Oral Solid Dosage Contract Manufacturing Market - Global Forecast 2025-2032

The oral solid dosage contract manufacturing market is rapidly evolving as pharmaceutical organizations seek efficient, scalable, and compliant solutions to meet dynamic global demands. This research report offers senior decision-makers a comprehensive analysis of prevailing trends, regulatory factors, and strategic growth opportunities reshaping the sector.

Market Snapshot: Oral Solid Dosage Contract Manufacturing Market Growth

The oral solid dosage contract manufacturing market grew from USD 44.16 billion in 2024 to USD 48.20 billion in 2025, demonstrating strong momentum. With an expected CAGR of 8.95%, the market is set to reach USD 87.70 billion by 2032. This sustained growth reflects the sector’s crucial role in worldwide pharmaceutical supply chains and its ability to adapt to shifting regulatory and economic landscapes.

Scope & Segmentation of the Market

This report provides an in-depth examination of oral solid dosage contract manufacturing, segmented by multiple criteria to help organizations tailor strategies and investments. Key segmentation categories include:

• Form Type: Capsules (hard gelatin, soft gelatin), granules (immediate release, modified release), pellets (coated pellets, multiparticulate), and tablets (coated, uncoated).
• Therapeutic Area: Anti-infectives (antibiotics, antivirals), cardiovascular (hyperlipidemia, hypertension), central nervous system (depression, epilepsy), gastrointestinal (acid reducers, prokinetics), oncology (hematological, solid tumor).
• Application: Over the counter, prescription drugs.
• Stage: Clinical trial, commercial.
• Customer Type: Biotechnology, nutraceutical, pharmaceutical.
• Regions: Americas (United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland, United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel, South Africa, Nigeria, Egypt, Kenya), and Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan).
• Key Companies: Catalent, Thermo Fisher Scientific, Lonza, Recipharm, Siegfried Holding, Fareva, PCI Pharma Services, Aurobindo Pharma, Ajinomoto Bio-Pharma Services, Piramal Pharma.

Key Takeaways for Senior Decision-Makers

• Strategic collaborations between pharmaceutical sponsors and contract manufacturers are driving accelerated product launches and fostering technological innovation.
• Emphasis on regulatory compliance ensures product quality, process consistency, and mitigates risk across complex global markets.
• Customization in manufacturing, including modular facilities and flexible production systems, enables rapid adaptation to fluctuating demand and evolving therapeutic needs.
• Sustainability initiatives, such as greener technologies and renewable energy use, are becoming integral to operational strategies in response to ESG expectations and shifting customer preferences.
• Geographic variations in infrastructure, regulatory models, and workforce considerations demand region-specific investment and partnership approaches for sustained growth and risk management.

Assessing the Impact of 2025 United States Tariffs

The implementation of new United States tariffs in 2025 has affected the oral solid dosage contract manufacturing industry, increasing production expenses due to higher duties on critical raw materials and excipients. In light of these changes, companies are revisiting sourcing strategies, reinforcing procurement teams, and prioritizing nearshoring to enhance operational flexibility. Adoption of blockchain and digital supply chain tools is improving transparency and supporting proactive risk assessment in response to these economic shifts.

Oral Solid Dosage Contract Manufacturing Market: Methodology & Data Sources

This research leverages a robust dual-method approach. Primary data was gathered through interviews with senior executives from contract manufacturing organizations, pharmaceutical sponsors, and regulatory agencies, capturing real-world perspectives on challenges and innovations. Comprehensive secondary analysis included industry publications and regulatory filings, triangulated with patent, clinical, and trade data to ensure accuracy and identify emerging trends.

Why This Report Matters

• Enables stakeholders to benchmark strategic positioning amid evolving regulatory requirements and tariff impacts.
• Offers granular segmentation and regional analysis to guide investment decisions and partnership development.

Conclusion

Senior leaders will benefit from this detailed view of the oral solid dosage contract manufacturing market, informed by rigorous analysis and direct industry insight. The report delivers actionable intelligence for navigating growth, compliance, and sustainability in today’s dynamic global environment.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.